Research programme: cancer therapeutics - Bayer HealthCare/National University of Singapore
Latest Information Update: 31 Mar 2011
At a glance
- Originator Bayer Schering Pharma; National University of Singapore
- Developer Bayer HealthCare Pharmaceuticals; National University of Singapore
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
- 30 Sep 2008 Preclinical trials in Cancer in Singapore (unspecified route)